Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.

Hepatology international - 1 May 2017

Sidhu Sandeep Singh, Malhi Nirmaljeet Singh, Goyal Omesh, Singh Rupinder, Dutta Usha, Grover Rajiv, Sidhu J S, Nanda Vijay, Saluja Harmeet, Bansal Ajesh, Singh Gursewak, Sehgal Alok, Kishore Harsh, Sidhu Simran

Abstract excerpt

BACKGROUND AND AIMS: Recently, Sofosbuvir was launched in India at affordable cost. We conducted a real-life study to determine the efficacy and safety of Sofosbuvir plus Ribavirin, with and without peginterferon-alfa 2a, in patients with chronic hepatitis C (CHC) genotype 3, the commonest genotype in South Asia. METHODS: This study included data of CHC patients from 11 sites in northern India between March 2015...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asia
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Ribavirin

Share to RNA Viruses

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Identifiers

PMID: 28361300
DOI: 10.1007/s12072-017-9794-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.PMID 28361300Read ↗

Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice.Semantic proximity Read ↗

Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.Semantic proximity Read ↗

Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.Semantic proximity Read ↗

Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir plus Ribavirin for chronic hepatitis C virus genotype 3 infected cirrhotic patients with or without HIV or HBV coinfection: Real-world experience from Southwest ChinaSemantic proximity Read ↗

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?Semantic proximity Read ↗

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.Semantic proximity Read ↗

Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.Semantic proximity Read ↗

Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.Semantic proximity Read ↗

Findings from a large Asian chronic hepatitis C real-life study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.